Leading Science this Spring & Summer
Discover ELRIG’s quarter two events – three focused scientific meetings showcasing the newest technologies, models, and strategies redefining drug discovery. Join global experts advancing complex cellular systems, automation, and innovative target screening.
ELRIG is a UK-based, not-for-profit organisation with 25 years’ experience connecting the global life science & drug discovery industry through open-access, free-to-attend events.
Advances in Cell-based Screening in Drug Discovery 2026
6-7 May – AstraZeneca, Gothenburg, SE
This event unites leaders from pharma, academia, and technology innovation to explore how to build the post‑animal, AI‑enabled drug discovery pipeline. Sessions examine how biologically relevant in vitro models, large‑scale multiplexed assays, and AI/ML are reshaping decision‑making in early discovery.
Delegates will gain insights into redesigning workflows for high‑content cellular readouts, integrating automation to handle data at scale, and preparing R&D teams for next‑generation predictive discovery.
Key Learnings
- How to generate and manage large‑ scale, multi‑dimensional cellular datasets.
- Practical approaches to engineering complex in vitro models at scale.
- How AI and ML can enhance prediction and reduce reliance on animal models.
ELRIG FORUM
Innovations in Translational Models: Replacing In Vivo Models with Complex Cellular Systems
22 April – Loughborough University, UK
This meeting showcases advances in complex cellular systems, NAMs, and animal‑replacement technologies reshaping translational research. As science shifts toward human‑relevant, mechanism‑driven models, this event offers practical guidance for adopting organoids, microphysiological systems, and next‑generation co‑culture platforms. Delegates will explore regulatory momentum, operational considerations, and best practices for embedding these technologies into existing pipelines, ensuring robust and predictive discovery.
Key Learnings
- How emerging complex cellular and NAM technologies enhance translational value.
- Strategies to reduce or replace animal studies without compromising scientific quality.
- Implementation tips for assay design, validation, and operational integration.
Drug Discovery Europe
Part of Discovery & Development Europe 2026
15-16 June – Berlin, Germany
This track highlights breakthroughs accelerating target identification, validation, and screening. Sessions explore functional genomics, CRISPR‑based discovery, AI‑driven repurposing, multi‑omics integration, and novel computational and biochemical screening strategies. Delegates will gain insights through case studies covering emerging modalities including PROTACs, ADCs, molecular glues, and AI‑enhanced digital R&D technologies. Designed for scientists advancing early‑stage discovery, this track provides a clear view of the tools and methods pushing scientific boundaries.
Key Learnings
- How emerging technologies accelerate target identification and validation.
- Best practices for integrating multi‑omics, CRISPR, and AI‑driven approaches.
- Insights into novel therapeutic modalities shaping early R&D.
Unsplash+